Sonoscape Medical Corp. Class A

Sonoscape Medical Corp. Class A

SSZSE:300633
21.04
CNY
-0.33
(-1.54%)
0.41EPS
47.42P/E
8.25BMarket Cap
Apr 09Next Earn

Total Valuation

CNY

As of September 30, 2026, Sonoscape Medical Corp. Class A carries a market capitalization of 8.25B, placing it among publicly traded companies globally. Its enterprise value stands at 7.61B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.25B
Enterprise Value7.61B

Important Dates

Sonoscape Medical Corp. Class A's next confirmed earnings release is scheduled for April 9, 2027.

Earnings Date4/9/2027

Share Statistics

As of September 30, 2026, Sonoscape Medical Corp. Class A has 424.84M shares outstanding.

Shares Outstanding424.84M

Valuation Ratios

As of September 30, 2026, Sonoscape Medical Corp. Class A trades at a trailing price-to-earnings ratio of 47.42. The price-to-sales ratio is 3.41, and the price-to-book ratio stands at 2.74.

PE Ratio47.42
PS Ratio3.41
PB Ratio2.74
P/TBV Ratio2.98

Enterprise Valuation

As of September 30, 2026, Sonoscape Medical Corp. Class A trades at an EV/EBITDA multiple of 49.03 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.12 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 49.03 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 7.61B versus a market cap of 8.25B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.12
EV / EBITDA49.03
EV / EBIT49.03

Financial Position

As of September 30, 2026, Sonoscape Medical Corp. Class A maintains a current ratio of 2.80, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.06, indicating elevated leverage, while an interest coverage ratio of 36.10 demonstrates strong ability to service its debt obligations.

Current Ratio2.80
Quick Ratio1.18
Debt / Equity12.06
Debt / EBITDA2.34
Interest Coverage36.10

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Sonoscape Medical Corp. Class A posted a return on equity (ROE) of 5.72, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 4.30, measuring how efficiently the asset base is converted into earnings. The company generates approximately 778,185.62 in revenue per employee across its workforce of 3,133.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.06 indicates how many times Sonoscape Medical Corp. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)5.72
Return on Assets (ROA)4.30
Revenue Per Employee778,185.62
Employee Count3,133.00
Inventory Turnover1.06

Taxes

CNY

Over the twelve months ended September 30, 2026, Sonoscape Medical Corp. Class A recorded an income tax benefit of -20.89M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 154.38M, leaving 175.27M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax-20.89M

Stock Price Statistics

CNY

As of the close on November 17, 2026, Sonoscape Medical Corp. Class A's stock has declined approximately 27.82% over the past 52 weeks. The 50-day moving average sits at 20.22, while the 200-day moving average is 22.31.

52-Week Price Change-27.82%
50-Day Moving Average20.22
200-Day Moving Average22.31

Income Statement

CNY

Over the twelve months ended September 30, 2026, Sonoscape Medical Corp. Class A generated 2.44B in revenue and converted that into 175.27M in net income, yielding earnings per share of 0.41. EBITDA reached 155.28M, while operating income came in at 248.92M.

Revenue2.44B
Gross Profit1.52B
Operating Income248.92M
Pretax Income154.38M
Net Income175.27M
EBITDA155.28M
EBIT155.28M
Earnings Per Share (EPS)0.41

Balance Sheet

CNY

As of September 30, 2026, Sonoscape Medical Corp. Class A holds 1.00B in cash and equivalents against 363.55M in total debt, resulting in a net debt position of -615.26M. Total book value stands at 3.01B, with working capital of 1.53B providing operational flexibility.

Cash & Cash Equivalents1.00B
Total Debt363.55M
Net Debt-615.26M
Equity (Book Value)3.01B
Book Value Per Share7.09
Working Capital1.53B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-154.14M

Margins

Over the twelve months ended September 30, 2026, Sonoscape Medical Corp. Class A posted a gross margin of 62.16, reflecting its pricing power and cost economics. The operating margin of 10.21 and net profit margin of 7.19 provide insight into operational efficiency.

Gross Margin62.16
Operating Margin10.21
Pretax Margin6.33
Profit Margin7.19
EBITDA Margin6.37

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Sonoscape Medical Corp. Class A paid dividends of 0.19 per share. The dividend payout ratio of 45.80 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 2.59, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sonoscape Medical Corp. Class A shareholders.

Dividend Per Share0.19
Payout Ratio45.80
Shareholder Yield2.59

Scores

As of September 30, 2026, Sonoscape Medical Corp. Class A has an Altman Z-Score of 6.27, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score6.27